Therapeutic Response

HRD, not BRCA1 oncogenic variants, not BRCA1 pathogenic variants, not BRCA2 oncogenic variants, and not BRCA2 pathogenic variants status confers therapeutic sensitivity to Rucaparib in patients with Peritoneal Serous Carcinoma.

Statements

Source and description